5. REFERENCES

1. Shah V. (2003), Transdermal drug delivery system regulatory issues, Marcel Dekker, New York, 361-367.

2. Robinson J., Controlled Drug Delivery, Marcel Dekker, Inc., Madison Avenue, New York, 2nd Edn., 29, 524-526.

2. Lachman and Lieberman (1991), The Theory and Practice of Industrial Pharmacy, Varghese Publishing house, 3rd Edn., 536-537.

3. Jain N., Misra (2005), Controlled and Novel Drug Delivery, CBS Publishers and Distributors, New Delhi.

4. Ansel H., Popovich P. (2005), Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th Edn., B. I. Publications Pvt. Ltd., 418.

5. Zatz J., Lieberman H., Rieger M., Banker G. (2005), Pharmaceutical dosage form: Disperse system, New York: Marcel Dekker, 2nd ed., 399-421.

6. Mikari B. (2010), Formulation and evaluation of topical liposomal gel for fluconazole, Indian J .Pharm.Sci., 44(4), 324-325.

7. Glavas D. (2003), 5-Flurouracil in topical liposome gels for anticancer treatment– formulation and evaluation, Maja Simonoska, Act a pharm, 53, 241-250.

8. Rupal J., Setty C. (2010), Preparation and evaluation of topical gel Valdecoxib. Dipti Patel, Int. J. Pharm. Sci. Research., 2(1), 51-54.

9. Larson R. (1999), The structure and rheology of complex fluids. Oxford University Press, New York.

10. Goyal S., Sharma P. (2011), Novel anti-inflammatory topical gels, International Journal of Pharmaceutical and Biological Archives, 2(4): 1087-1094.

11. Nacht S., Kantz M. (1992), The Microsponge: A Novel Topical Programmable Delivery System, Topical Drug Delivery Systems, 42: 299-325.

12. Aritomi H., Yamasaki Y. (1996), Development of sustained release formulation of chlorpheniramine maleate using powder coated microsponges prepared by dry impact blending method, Journal of Pharmaceutical Sciences and Technology, 56(1): 49-56.

13. Parthiban K., Manivannan R., (2011), Microsponge role in novel drug delivery system, International journal of pharmaceutical research and development, 3(4), 117-125.

14. Panwar A., Yadav C., Jain D. (2011), Microsponge a novel carrier for cosmetics, J Global Pharma Technology 3(7), 15-24.
15. Vyas S., Khar R. (2002), Targeted and controlled drug delivery- Novel carrier system, CBS Publication, New Delhi, Edition 1, 453.
16. Delattre L., Delneuville I. (1995), Biopharmaceutical aspects of the formulation of dermatological vehicles, J. Eur. Acad. Dermatol. Venereol, 5, 70-71.
17. Delattre L., Delneuville I. (1995), Biopharmaceutical aspects of the formulation of dermatological vehicles, J Eur. Acad. Dermatol. Venereol, 5, 81.
18. Embil K., Nacht S. (1996), The microsponge delivery system (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives, J. Microencapsulation, 308, 124-132.
19. Viral S. (2010), Microsponge drug delivery system: A review, Int. J. Res. Pharm. Sci 1, 212-218.
20. Kawashima Y. (1992), Control of Prolonged Drug Release and Compression Properties of Ibuprofen Microsponges with Acrylic Polymer, Eudragit RS, by Changing Their Intraparticle Porosity, Chemical & pharmaceutical bulletin 40(1), 196-201.
21. Jelvehgari M., Nokhodchi A. (2006), The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies, Int J Pharma, 308, 124-132.
22. Amrutiya N., Bajaj A., Madan M. (2009), Development of microsponges for topical delivery of mupirocin. AAPS Pharm. Sci. Tech., 10(2):402-409.
23. Lawrence X., Raw A. (2007), U.S. FDA question-based review for generic drugs: A new pharmaceutical quality assessment system, J. Generic Med, 4, 239–248.
24. Food and Drug Administration CDER (2006), Guidance for industry, Q8 pharmaceutical development.
25. Nasr M., Risk-based CMC review paradigm (2004), Advisory committee for pharmaceutical science meeting.
26. Food and Drug Administration CDER (1995), Guidance for industry: Immediate release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation.

27. Food and Drug Administration CDER (1997), Guidance for industry: Modified release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation.
28. Food and Drug Administration CDER (1997), Guidance for industry: Non sterile semisolid dosage forms scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation.
29. Food and Drug Administration CDER. Guidance for industry (2004), Changes to an approved NDA or ANDA.
30. Woodcock J. (2004), The concept of pharmaceutical quality, Am. Pharm. Rev, 1–3.
31. Food and Drug Administration Office of Generic Drugs White Paper on Question-based Review: http://www.fda.gov/cder/ OGD/QbR.htm.
32. Food and Drug Administration CDER (1999), Guidance for industry, Q6A specifications for new drug substances and products: Chemical substances.
33. Nasr M. (2007), FDA's quality initiatives: An update. http://www.gmpcompliance.com/daten/download/FDAs_Quality_Initiative.pdf; 2007.
34. Shesky P., Weller P., Handbook of Pharmaceutical exicipients, The Pharmaceutical press., 4th ed. London, 237.
35. Mathew S., Devi S. (2007), Formulation and evaluation of ketorolac tromethamine-loaded albumin microspheres for potential intramuscular administration, AAPS PharmSciTech, 8(1), E1-E9.
36. Ghosh A., Nayak U., Development, evaluation and method selection for the preparation of lamivudine microspheres.
37. Yerram C., Shaikfiroz, R., Amaravathivikram,B. (2012), Preparation and Evaluation of Microsponge loaded Controlled Release Topical Gel of Acyclovir Sodium, *Int. J. Pharm*., 3(2), 96-102.
38. Vaibhav G. (2013), Design and Optimization of Colon Targeted Microspheres of Prednisolone Sodium Phosphate using Quality by Design Approach, Indo American Journal of Pharmaceutical Research, 3 (5), 56-61.
39. Namrata V. (2013), Development and in-vitro evaluation of an optimized carvedilol transdermal therapeutic system using experimental design approach, Asian journal of pharmaceutical science, 8, 28 -38.

40. Mehta M., Panchal A. (2012), "Formulation and Vitro Evaluation of Controlled Release Microsponge Gel for Topical Delivery of Clotrimazole", International Journal of Advanced Pharmaceutics, 2(2), 93-101.
41. Nevine S. (2002), new topical fluconazole loaded hydrogel: preparation and characterization, Int. J. Pharm, 4, 0975-1491.
42. Badir D. (2012), Design of Vancomycin RS-100 Nanoparticles in order to increase the Intestinal Permeability, Advanced Pharmaceutical Bulletin, 2(1), 43-56.
43. Varun T. (2012). Formulation and in vitro Evaluation of Gel for Topical Delivery of Antifungal Agent Fluconazole Using Different Penetration Enhancers, Drug Invention Today.
44. Vinod L., Vishal D. and Rakesh P. (2012), Effect of Carbopol 934 and 940 on Fluconazole Release from Topical Gel Formulation: A Factorial Approach. Current Pharma Research, 2(2), 487-493.
45. Baksh A. (2012), Formulation and in –vitro evaluation of NSAID'S gel, International journal of current pharmaceutical research, 4(3), 285-290.
46. Niyaz B., Kalyani P. (2011), Formulation and Evaluation of Gel containing Fluconazole-Antifungal Agent, International Journal of Drug Development & Research, 3(4), 0975-9344.
47. Japan P., Brijesh P. and Hardeepsingh B. (2011), Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent, International Journal of Drug Development & Research, 3(1), 0975-9344
48. Nitesh S, Mayur P. and Tejal S. (2011), Design, Development and Optimization of Colon Targeted Drug Delivery System for Crohnís Disease, J Pharm Educ. Res, 2(1), 22-27.
49. Sabyasachimaiti S. (2011), Development and evaluation of xanthan gum-facilitated ethyl cellulose microsponges for controlled percutaneous delivery of Diclofenac sodium, Acta Pharm., 1(4), 257–270.
50. Swetha A., Gopal M. and Venkata R. (2011), Formulation and in-vitro Evaluation of Etodolac Entrapped in Microsponge based Drug Delivery System, Int J Pharma.,1(2),73-80.

51. Mishra M., Shikhri M. and Sharma R. (2011), Optimization, Development and Characterization of Eudragit RS 100 loaded Microsponges and Subsequent Colonic Delivery, Int. J. of Drug Discovery and Herbal Research, 1(1), 8-13.
52. Shiv K., Aakash S. and Gajanan D. (2011), Formulation and Evaluation of Fluconazole Amphiphilogel, Scholars Research Library, 3 (5), 125-131.
53. Swati J., Dhaval B. and Mahesh G. (2011), Formulation and Evaluation of Fluconazole Soap Strips for Dermal Infections, International Journal of Pharm Tech Research,3(4), 2215-2221.
54. Senthil K., Ashokkumar S. and Ezhilmuthu R. (2010), Formulation and Evaluation of Didanosine Enteric Coated Sustained Release Tablet, J Biomed Sci and Res., 2 (3), 126-131.
55. Sudhamani T., Noveenkumar P. (2010), preparation and evaluation of ethyl cellulose microspheres of ibuprofen for sustained drug delivery, IJPRD, 2(8), 38-43.
56. Gaddam N. and Aukunuru J. (2010), Systemic Del, Topical Application of Gels Incorporated With Drug-Loaded Solid Lipid Nanoparticles(SLN), Journal of Pharmaceutical Research, 2(2), 177- 187.
57. Jain V. and Singh R. (2011), Development and Characterization of drug Loaded Microsponges and its Colonic Delivery System containing Paracetamol microsponges, Arch pharm Reserch, 34(5), 733-740.
58. Vikas J. and Ranjit S. (2010), Development and Characterization of Eudragit RS 100 loaded microsponges and its colonic delivery using natural polysaccharides, Act a Poloniae Pharmaceutica - Drug Research, 64(4), 407-415.
59. Modha1 N., Chotai1 P. (2010), Preparation, Characterization and Evaluation of Fluconazole Polymorphs, International Journal of Research in Pharmaceutical and Biomedical Sciences, 1(2), 78-84.
60. Mitkari B. (2009), Formulation and Evaluation of Topical Liposomal Gel for Fluconazole, Indian J.Pharm. Educ. Res, 44(4).
61. Rohit S., Chandrakant S. and Kiran A. (2009), Fluconazole Topical Microemulsion: Preparation and Evaluation, Research J. Pharm. and Tech., 2(2).

62. Behera B. (2008), Characterization Of Glipizide-Loaded Polymethacrylate Microspheres Prepared By An Emulsion Solvent Evaporation Method, Tropical Journal of Pharmaceutical Research, 7 (1), 879-885.

63. John I (2008), Topical Anti-Inflammatory Gels of Fluocinolone Acetonide Entrapped in Eudragit Based Microsponge Delivery System, Research J. Pharm. and Tech., 1(4), 502-506.

64. Nokhodchi A., Jelvehgari M. and Siahi M. (2007), Factors Affecting the Morphology of Benzoyl Peroxide Microsponges, Micron online journal, 38,834-840.

65. Orlu M., Cevher E. and Araman A. (2006), Design and Evaluation of Colon Specific Drug Delivery System Containing Flurbiprofen Microsponges, Int. J. Pharm., 318,103-117.

66. Jelvehgari M., Siahi-Shadbad M. and Azarmi S. (2006), The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies, Int. J. Pharm., 308,124-32.

67. Tansel C., Nursin G. and Tamer B (2003), Preparation and in vitro evaluation of modified release ketoprofen microsponges, II Farmaco, 58,101-106.

68. Nursin G. and Tamer B. (2002), The Effects of Pressure and Direct Compression on Tabletting of Microsponges. Int. J. Pharm., 242,191–195.